Yan Leyfman

Morton Coleman, MD is the Founding Chair, LL&M Congress. He has been an Attending Physician at the New York-Presbyterian Hospital/Weill Cornell Medical Center and a Clinical Professor of Medicine at Weill Cornell Medicine. He was the Director of the Center for Lymphoma and Myeloma, the chairman of the Medical Affiliates Board of the Lymphoma Research Foundation, President of the New York Cancer Society, the chairman of Clinical Research Alliance, among many prestigious appointments. He has served on numerous scientific boards. Dr Coleman has received numerous awards including those from the Cure for Lymphoma Foundation, the Lymphoma Research Foundation, The Waldenstrom's Foundation, Cornell University and Old Dominion University among others. He has authored hundreds of publications primarily in myeloma, lymphoma, and chronic lymphocytic leukemia. Among his many seminal observations were the development of the standard of care for Hodgkin disease for over 40 years, the first use of effective novel agents in myeloma, metronomic therapy for hematologic diseases, and the use of combination monoclonal antibody therapy, among others. He founded the Lymphoma, Leukemia, and Myeloma Conference a quarter of a century ago.

Gail J. Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA.

Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital.

Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on measurable residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Dr. Yan Leyfman is a hematology-oncology fellow and clinician-investigator whose work bridges cellular immunotherapy, artificial intelligence (AI), and global health equity. Recognized among the "40 Under 40 Emerging Leaders in Cancer" at the 2023 ASCO Annual Meeting, his research focuses on advancing innovative cancer therapies, integrating AI into precision oncology, and expanding equitable access to cancer care.

During the COVID-19 pandemic, Dr. Leyfman led the Immunology Division of the Global COVID-19 Taskforce, advancing research on SARS-CoV-2 and the intersection of cancer and COVID-19. His subsequent work has focused on CAR T-cell therapies, immuno-oncology, and AI-driven approaches to cancer care, including a collaboration with investigators at Mount Sinai and Memorial Sloan Kettering Cancer Center on predicting immunotherapy response, published in Nature Medicine.

His contributions have received international recognition, including the 2023 Phacilitate Advanced Therapies Young Scientist Award, the 2024 Lymphoma, Leukemia & Myeloma Congress Hero in Healthcare Award, the 2023 & 2026 ASCO Breakthrough Conquer Cancer Merit Awards, and the 2025 CSNY Higher Education Trailblazer Award.

As Co-Founder and Executive Director of MedNews Week, Dr. Leyfman leads a global medical education platform reaching more than 150 countries. Through research, education, and mentorship, he is committed to combating medical misinformation, reducing healthcare disparities, and translating scientific innovation into more accessible and equitable cancer care worldwide.